{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:16:41Z","timestamp":1794619001401,"version":"4.9.1"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101317","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T02:40:38Z","timestamp":1749609638000},"page":"101317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Novel therapies for acute myeloid leukemia. Does age still matter?"],"prefix":"10.1016","volume":"74","author":[{"given":"Baher","family":"Krayem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Frisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netanel","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101317_bb0005","unstructured":"Acute Myeloid Leukemia \u2014 Cancer Stat Facts n.d. https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html (accessed September 24, 2023)."},{"key":"10.1016\/j.blre.2025.101317_bb0010","article-title":"Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: a real-world, population-based longitudinal cohort study","volume":"19","author":"Han","year":"2024","journal-title":"PloS One"},{"key":"10.1016\/j.blre.2025.101317_bb0015","series-title":"Acute Myeloid Leukemia","author":"Vakiti","year":"2023"},{"key":"10.1016\/j.blre.2025.101317_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2016.1.339","article-title":"Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction","volume":"2016","author":"Rao","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101317_bb0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0030","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101317_bb0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0040","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-025-01258-0","article-title":"Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial","volume":"15","author":"Hoff","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101317_bb0050","article-title":"Aging and comprehensive molecular profiling in acute myeloid leukemia","volume":"121","author":"Li","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2025.101317_bb0055","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","article-title":"Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older","volume":"103","author":"Prassek","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101317_bb0060","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0065","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0070","first-page":"40","article-title":"The golden age for patients in their golden years: the progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia","author":"Shallis","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2025.101317_bb0075","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2025.101317_bb0080","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2023-189734","article-title":"Older adults with acute myeloid leukemia (AML) experience improvement in health-related quality of life (HRQoL) scores with intensive therapy: prospective study from ECOG-ACRIN (EA) E2906 phase 3 trial","volume":"142","author":"Foran","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0085","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V126.23.217.217","volume":"126","author":"Foran","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3727\/096504014X14146137738547","article-title":"Intensive chemotherapy in patients aged 70 years or older newly diagnosed with acute myeloid leukemia","volume":"22","author":"Ross","year":"2015","journal-title":"Oncol Res"},{"key":"10.1016\/j.blre.2025.101317_bb0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101317_bb0100","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000362777","article-title":"Selection of elderly acute myeloid leukemia patients for intensive chemotherapy: effectiveness of intensive chemotherapy and subgroup analysis","volume":"133","author":"Kim","year":"2015","journal-title":"Acta Haematol"},{"key":"10.1016\/j.blre.2025.101317_bb0105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2013.092072","article-title":"Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification","volume":"99","author":"Wetzler","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101317_bb0110","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","article-title":"CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial","volume":"8","author":"Lancet","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101317_bb0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-142990","article-title":"CPX351 has short remission duration but is an effective bridge to allogeneic transplant in high risk AML: results from Canadian real-world multi-centre study","volume":"136","author":"Andrews","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0120","first-page":"10","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","author":"Guolo","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101317_bb0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.103984","article-title":"Real-world experience with CPX-351 in high-risk acute myeloid leukemia","volume":"185","author":"Lemoli","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2025.101317_bb0135","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1016\/j.clml.2023.07.003","article-title":"Real-world experience with CPX-351 treatment for acute myeloid leukemia in England: an analysis from the National Cancer Registration and analysis service","volume":"23","author":"Legg","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2025.101317_bb0140","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.clml.2022.06.001","article-title":"CPX-351 yields similar response and survival outcome in younger and older patients with secondary acute myeloid leukemia","volume":"22","author":"Lee","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2025.101317_bb0145","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2023-185052","article-title":"Daunorubicin\/cytarabine liposome +\/\u2212 gemtuzumab ozogamicin for adult patients with newly diagnosed, low-intermediate risk, FLT3-wild type, AML: a pilot study","volume":"142","author":"Ganzel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0150","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2022-159680","article-title":"V-FAST master trial: subgroup analysis of outcomes with CPX-351 plus midostaurin in adults with newly diagnosed acute myeloid leukemia by FLT3 mutation type","volume":"140","author":"McCloskey","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0155","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101317_bb0165","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0170","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive Care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0175","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0180","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0185","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III children\u2019s oncology group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0190","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug","volume":"121","author":"Rowe","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0195","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1182\/blood-2022-165021","article-title":"High response and prolonged treatment-free remission after a Short-course of modified intensive chemotherapy and venetoclax in elderly AML: an updated analysis of the caveat trial","volume":"140","author":"Chua","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0200","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-Escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0205","unstructured":"Acute Myeloid Leukemia - Guidelines Detail n.d. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411 (accessed September 9, 2024)."},{"key":"10.1016\/j.blre.2025.101317_bb0210","series-title":"Venetoclax and azacitidine for newly diagnosed non-elderly adult patients with acute myeloid leukemia and adverse risk features","author":"Pollyea","year":"2020"},{"key":"10.1016\/j.blre.2025.101317_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2021-153288","article-title":"Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00277-021-04693-8","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study","volume":"101","author":"Pasvolsky","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2025.101317_bb0225","article-title":"Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-024-01130-7","article-title":"Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: a propensity score-matched analysis based on international consensus classification","volume":"14","author":"Wan","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101317_bb0235","unstructured":"Venetoclax + Decitabine vs. \u201c7+3\u201d Induction Chemotherapy in Young AML - Full Text View - ClinicalTrials.gov n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05177731?term=Venetoclax+chemotherapy&cond=aml&draw=2&rank=1 (accessed February 19, 2024)."},{"key":"10.1016\/j.blre.2025.101317_bb0240","unstructured":"Venetoclax + Azacitidine vs. Induction Chemotherapy in AML - Full Text View - ClinicalTrials.gov n.d. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04801797?term=Venetoclax+chemotherapy&cond=aml&draw=2&rank=8 (accessed February 19, 2024)."},{"key":"10.1016\/j.blre.2025.101317_bb0245","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0250","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood-2023-187695","article-title":"N\/KRAS-mutant AML LSCs originate from committed Myelomonocytic progenitors and drive clinical resistance to Venetoclax","volume":"142","author":"Sango","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101317_bb0260","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1080\/10428194.2023.2190432","article-title":"Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia","volume":"64","author":"Mustafa Ali","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2025.101317_bb0265","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2025.101317_bb0270","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","article-title":"Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial","volume":"8","author":"Kadia","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101317_bb0275","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/blood-2024-204627","article-title":"For patients with adverse-risk acute myeloid leukemia, frontline FLAG Ida with venetoclax is safe and efficacious","volume":"144","author":"Krayem","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0280","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0285","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0290","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","article-title":"FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia","volume":"110","author":"Mead","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0295","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101317_bb0300","unstructured":"Midostaurin | FDA n.d. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/midostaurin (accessed February 26, 2024)."},{"key":"10.1016\/j.blre.2025.101317_bb0305","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"D\u00f6hner","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101317_bb0310","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-first): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101317_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00670-0","article-title":"Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML","volume":"12","author":"Yilmaz","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2025.101317_bb0320","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3 -mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0325","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus Gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","author":"Daver","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0330","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101317_bb0335","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood.2020007233","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","volume":"137","author":"Stein","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0340","unstructured":"Study Details | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT03839771 (accessed May 12, 2025)."},{"key":"10.1016\/j.blre.2025.101317_bb0345","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1 -mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101317_bb0350","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101317_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-024-01657-z","article-title":"Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1\/2 trial","volume":"18","author":"Cortes","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0360","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.blre.2025.101317_bb0365","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.blre.2025.101317_bb0370","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.blre.2025.101317_bb0375","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","author":"Issa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101317_bb0380","unstructured":"FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation | FDA n.d. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation (accessed May 12, 2025)."},{"key":"10.1016\/j.blre.2025.101317_bb0385","unstructured":"Title: PHASE 1B STUDY OF AZACITIDINE, VENETOCLAX AND REVUMENIB IN NEWLY DIAGNOSED OLDER ADULTS WITH NPM1 MUTATED OR KMT2A REARRANGED AML: INTERIM RESULTS OF DOSE ESCALATION FROM THE BEATAML CONSORTIUM Abstract Type: Oral Presentation Session Title: Acute myeloid leukemia-Clinical 1-Menin inhibitor Background n.d."},{"key":"10.1016\/j.blre.2025.101317_bb0390","unstructured":"Study Details | A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/study\/NCT06226571 (accessed May 12, 2025)."},{"key":"10.1016\/j.blre.2025.101317_bb0395","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101317_bb0400","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood-2024-202576","article-title":"Real world outcomes of oral azacitidine maintenance therapy for acute myeloid leukemia: a single center experience","volume":"144","author":"Tuz Zahra","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0405","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood-2024-198362","article-title":"Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia","volume":"144","author":"Krishnamurthy","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101317_bb0410","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/cpt.2982","article-title":"Population pharmacokinetics of oral azacitidine, and exposure-response analysis in acute myeloid leukemia","volume":"114","author":"Gaudy","year":"2023","journal-title":"Clin Pharmacol Ther"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:38:32Z","timestamp":1766079512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":82,"alternative-id":["S0268960X25000621"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101317","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies for acute myeloid leukemia. Does age still matter?","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101317"}}